According to Cai Dongchen, chairman of the Shijiazhuang Group, although the Shijiazhuang Pharmaceutical Co., Ltd. has ranked among the top 500 Chinese companies for three times and was selected as the 500 most valuable brands in China, the production capacity of several products such as penicillin, vitamin C and amoxicillin ranks first in the world. One, but traditional Chinese medicine preparations have always been a shortcoming for enterprises. Yinhu Pharmaceutical has advanced technology and decades of experience in the production of traditional Chinese medicine preparations. Its products enjoy a good reputation throughout the country and are the national brands that the state supports and develops. “Stone Pharmaceutical Group is in a period of strategic transfer from raw material medicines to preparations. We urgently need strong companies such as Yinhu Pharmaceutical to join us,†Cai Dongchen said.
Stone Drug Group
It is understood that the Shijiazhuang Group will requisition 500 acres of land in the Yuncheng Salt Lake Industrial Park and invest RMB 250 million in the first phase to start 5 projects: build a new 100 million bottle glass container injection production line and build a new 100 million bottle plastic container injection annually In the production line, a new production line with an annual output of 50 million bags of soft bag injections will be built, and two new 20-ton steam boilers will be built. The final production capacity will be one billion Chinese medicine preparations and one billion infusion drug use per year. It is expected that the first phase of the project will be put into production next year. The sales volume for the next five years will reach RMB 1 billion, and the profits tax revenue will double within 10 years.